Karen Louise Thomsen is an academic Hepatologist at Aarhus University and Aarhus University Hospital, Denmark. She obtained her PhD from Aarhus University in 2012 under the supervision of Prof. Hendrik Vilstrup and completed her clinical training as a specialist in Hepatology and Gastroenterology in 2016. During her training, she spent time at the Storr Liver Unit, Sydney, Australia and at the Institute for Liver and Digestive Health, University College London.
Her research is focused on derangements of metabolic liver function, including the regulation of urea synthesis, and the impact of inflammation in liver disease. Her more recent studies have specifically focused on NAFLD and in collaboration with her colleagues in London, she has investigated a link between reduction in urea synthesis, hyperammonaemia and progression of NAFLD and cognitive dysfunction and NAFLD.
Her on-going clinical studies investigate urea synthesis and metabolic liver dysfunction in NAFLD patients through in vivo functional tests as well as MRI and PET imaging. Furthermore, she is the PI of a large, multicentre, randomised, double-blinded, placebo-controlled study investigating the effect of FMT for prevention of complications and mortality in patients with decompensated liver cirrhosis.